Lineage Cell Therapeutics, Inc. (LCTX) Return on equity 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-142.6%FY2025 · since FY2016: 28.5% → -142.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -142.6% | -118.9 pp |
| FY2024 | -23.7% | +10.1 pp |
| FY2023 | -33.9% | +1.9 pp |
| FY2022 | -35.8% | +10.8 pp |
| FY2021 | -46.6% | -25.2 pp |
| FY2020 | -21.5% | -11.1 pp |
| FY2019 | -10.4% | +39.5 pp |
| FY2018 | -49.9% | -37.6 pp |
| FY2017 | -12.3% | -40.8 pp |
| FY2016 | 28.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice